Atopic Dermatitis
Latest News
New guidelines for MTX use in pediatric inflammatory skin disease unveiled
One of the recommendations states that liver biopsy is not indicated for routine monitoring of pediatric patients taking low-dose MTX.
Latest News
Dupilumab outcomes stable at end of open label atopic dermatitis study
Other recent research on the biologic has shown that it improves lesional skin barrier function and rapidly reduces the abundance of ...
Latest News
JAK-inhibitor safety in adolescents with AD: Long-term analyses reported
For abrocitinib, "we're starting to get good numbers of [adolescents] who've had about 2 years of exposure," Dr. Lawrence Eichenfield said.
Latest News
Can online mindfulness and self-compassion training improve quality of life for patients with atopic dermatitis?
"Stress can make the skin worse, but at the same time the skin disease and symptoms cause stress," Dr. Peter A. Lio said.
Latest News
AD in infancy: Diagnostic advice and treatment tips
Among infants who are growing well and otherwise healthy, the infantile eczema phenotype encompasses AD, seborrheic dermatitis, contact dermatitis...
Latest News
Facial, hand, and foot dermatitis: Lebrikizumab and dupilumab show efficacy in new studies
"Lebrikizumab was efficacious in clearing and improving facial and hand dermatitis, burdensome and difficult-to-treat areas, in most patients," Dr...
Conference Coverage
Can this tool forecast peanut allergies?
The predictive scorecard captures 14 images from one infant of mixed race, two White infants, two Black infants, and two Hispanic infants.
From the Journals
Study focuses on adolescent data in upadacitinib AD trials
Upadacitinib was generally well tolerated among the adolescents, with mild or moderate acne being the most common adverse event.
Latest News
What are the clinical implications of recent skin dysbiosis discoveries?
Activities that can contribute to alterations in skin flora or skin dysbiosis include topical application of steroids, antibiotics, retinoids,...
Latest News
JAK inhibitor ivarmacitinib shows efficacy for atopic dermatitis in a pivotal trial
The co-primary endpoints were change in IGA and EASI scores at 16 weeks, and both improved rapidly, showing statistical significance relative to...
Latest News
Topical delgocitinib shows promise for chronic hand eczema, pivotal trial shows
Delgocitinib is an investigational topical pan-JAK inhibitor that inhibits activation of the JAK-STAT pathway.